Literature DB >> 14659650

Contemporary in vitro spectrum of activity summary for antimicrobial agents tested against 18569 strains non-fermentative Gram-negative bacilli isolated in the SENTRY Antimicrobial Surveillance Program (1997-2001).

Ronald N Jones1, Helio S Sader, Mondell L Beach.   

Abstract

The frequency of occurrence and antimicrobial susceptibility patterns of 18569 non-fermentative Gram-negative bacilli consecutively collected as part of the SENTRY Antimicrobial Surveillance Program were summarized. The isolates were tested by the broth microdilution method in three coordinator laboratories using common reagents and reference methodologies. The most frequently isolated pathogen was Pseudomonas aeruginosa (11968 isolates; 64.5%) followed by Acinetobacter spp. (3468 isolates; 18.7%) and Stenotrophomonas maltophilia (1488 isolates; 8.0%). The lowest resistance rates for P. aeruginosa documented were for amikacin (8%), meropenem (10%) and cefepime (10%), and all fluoroquinolones tested showed similar resistance rates (22-24%). The most active compounds against Acinetobacter spp. were the carbapenems, imipenem (11% resistance) and meropenem (12% resistance) followed by cefepime (31% resistance) and gatifloxacin (32% resistance). Very few compounds showed reasonable in vitro activity against S. maltophilia, with the most active antimicrobial agents being trimethoprim/sulphamethoxazole, gatifloxacin and levofloxacin (5-6% resistance). Resistance surveillance among these organisms remains necessary to guide empirical antimicrobial therapy, especially for these less frequently isolated and difficult to test pathogens.

Entities:  

Mesh:

Year:  2003        PMID: 14659650     DOI: 10.1016/s0924-8579(03)00245-0

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  23 in total

1.  Is the prevalence of Stenotrophomonas maltophilia isolation and nosocomial infection increasing in intensive care units?

Authors:  E Meyer; F Schwab; P Gastmeier; H Rüden; F D Daschner
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-11       Impact factor: 3.267

2.  Immunostimulatory properties of the emerging pathogen Stenotrophomonas maltophilia.

Authors:  Valerie J Waters; Marisa I Gómez; Grace Soong; Sunil Amin; Robert K Ernst; Alice Prince
Journal:  Infect Immun       Date:  2007-01-12       Impact factor: 3.441

3.  Clinical Features, Antibiotic Susceptibility Profile, and Outcomes of Infectious Keratitis Caused by Stenotrophomonas maltophilia.

Authors:  Sotiria Palioura; Allister Gibbons; Darlene Miller; Terrence P OʼBrien; Eduardo C Alfonso; Oriel Spierer
Journal:  Cornea       Date:  2018-03       Impact factor: 2.651

Review 4.  Stenotrophomonas maltophilia: Significant contemporary hospital pathogen - review.

Authors:  O Nyc; J Matejková
Journal:  Folia Microbiol (Praha)       Date:  2010-06-06       Impact factor: 2.099

Review 5.  Pharmacological considerations for the proper clinical use of aminoglycosides.

Authors:  Spyridon Pagkalis; Elpis Mantadakis; Michael N Mavros; Christina Ammari; Matthew E Falagas
Journal:  Drugs       Date:  2011-12-03       Impact factor: 9.546

6.  Stenotrophomonas maltophilia infection among young children in a cardiac intensive care unit: a single institution experience.

Authors:  Ciji Arthur; Xinyu Tang; Jose R Romero; Jeffrey G Gossett; Nada Harik; Parthak Prodhan
Journal:  Pediatr Cardiol       Date:  2014-10-08       Impact factor: 1.655

Review 7.  Meropenem: a review of its use in the treatment of serious bacterial infections.

Authors:  Claudine M Baldwin; Katherine A Lyseng-Williamson; Susan J Keam
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 8.  Management of meningitis due to antibiotic-resistant Acinetobacter species.

Authors:  Baek-Nam Kim; Anton Y Peleg; Thomas P Lodise; Jeffrey Lipman; Jian Li; Roger Nation; David L Paterson
Journal:  Lancet Infect Dis       Date:  2009-04       Impact factor: 25.071

9.  A Combination of Trimethoprim-sulfamethoxazole and Ceftazidime Showed Good In Vitro Activity against Stenotrophomonas maltophilia.

Authors:  Nabilah Ismail; Zarifah Zam; Siti Asma Hassan; Zaidah Abdul Rahman
Journal:  Malays J Med Sci       Date:  2017-04-14

Review 10.  Levofloxacin : a review of its use as a high-dose, short-course treatment for bacterial infection.

Authors:  Vanessa R Anderson; Caroline M Perry
Journal:  Drugs       Date:  2008       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.